The ENHANCE Study: taVNS and Psilocybin

PHASE1RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

January 31, 2028

Conditions
HealthyPsychedelic ExperiencesVagus Nerve Stimulation
Interventions
DRUG

Psilocybin

The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of botanically-derived psilocybin.

DEVICE

Transcutaneous auricular Vagus Nerve Stimulation (taVNS)

For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.

BEHAVIORAL

Psychosocial Support Alone

Participants assigned to Psychosocial Support Alone will not receive taVNS following psilocybin dosing.

OTHER

Sham taVNS

For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.

Trial Locations (1)

53715

RECRUITING

University of Wisconsin - Madison, Madison

All Listed Sponsors
collaborator

Tiny Blue Dot Foundation

OTHER

lead

University of Wisconsin, Madison

OTHER